Cerevance is a neuroscience focused drug discovery company dedicated to finding innovative new medicines for debilitating CNS disorders.  The company’s powerful NETSseq platform profiles cell-type-specific gene expression in post-mortem human brain tissue obtained from healthy and diseased donors with the aim of identifying novel targets for drug discovery.  We have built an exciting pipeline of novel discovery projects including clinical-stage compounds.

Cerevance is a venture-capital backed company located in Cambridge, UK and Boston, MA, USA.